Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer
NCT04018053Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluciclovine f 18 in bladder cancer, sponsored by Brigham and Women's Hospital. Primary endpoint: Agreement Rate of Metastatic Disease Status Between 18F-fluciclovine-PET/CT and Histopathology From Radical Cystectomy up to 24 hours. Started Feb 2020; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04018053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04018053.